ESMO 2022 Archives - Medical Conferences

Home > Oncology > ESMO 2022

European Society for Medical Oncology
09–13 September 2022
Paris, France

Letter from the Editor

Editor

Dr Stefan Rauh, the Centre Hospitalier Emile Mayrisch, Esch, Luxembourg

Colorectal Cancer

High pathological responses to neoadjuvant immune checkpoint inhibition in locally advanced dMMR colon cancer

Presented By

Dr Miriam Chalabi, Netherlands Cancer Institute, the Netherlands

Fruquintinib: a potential new treatment for patients with refractory mCRC

Presented By

Prof. Nageshwara Arvind Dasari, MD Anderson Cancer Centre, TX, USA

Second-line avelumab is effective in patients with MSI-H/dMMR mCRC

Presented By

Prof. Julien Taieb, Hopital European George Pompidou, France

Upper Gastrointestinal Cancer

Deep learning models predict the risk of relapse and the mutational profile in GIST

Presented By

Dr Raul Perret, Institute Bergonié, France

Addition of pembrolizumab to lenvatinib does not improve OS in advanced HCC

Presented By

Prof. Richard Finn, David Geffen School of Medicine, CA, USA

New, highly selective inhibitor of FGFR2 driver alterations and resistance mutations

Presented By

Prof. Antoine Hollebecque, Institut Gustave Roussy, France

Chemo-immunotherapy in gastric cancer is more effective when administered in parallel

Presented By

Prof. Sylvie Lorenzen, Klinikum rechts der Isar, TU München, Germany

Breast Cancer

Tumour infiltrating lymphocytes identify patients with immunogenic triple-negative breast cancer

Presented By

Prof. Marleen Kok, Netherlands Cancer Institute, the Netherlands)

OS benefit of abemaciclib in HR-positive/HER2-negative advanced breast cancer not (yet) statistically significant

Presented By

Prof. Matthew Goetz, Mayo Clinic Rochester, MN, USA

OS benefit of sacituzumab govitecan in pre-treated HR-positive/HER2-negative metastatic breast cancer

Presented By

Prof. Hope Rugo, Helen Diller Family Comprehensive Cancer Centre, CA, USA

Lung Cancer

A pathway from air pollution to lung cancer in non-smokers identified

Presented By

Prof. Charles Swanton, University College London, UK

Selective KRASG12C inhibitor sotorasib demonstrates superior PFS and ORR compared to docetaxel in previously treated patients with NSCLC

Presented By

Dr Melissa Johnson, Sarah Cannon Research Institute, TN, USA

Promising clinical activity of tepotinib plus osimertinib in NSCLC with MET amplification after progression on first-line osimertinib

Presented By

Prof. Julien Mazières, CHU de Toulouse, France

High pathological responses in borderline resectable NSCLC patients after induction with dual immunotherapy and concurrent chemoradiotherapy

Presented By

Dr Idris Bahce, Amsterdam UMC, the Netherlands

Melanoma

Treatment with tumour-infiltrating lymphocytes for advanced melanoma outperforms ipilimumab

Presented By

Prof. John Haanen, Netherlands Cancer Institute, the Netherlands

Neoadjuvant pembrolizumab outperforms adjuvant pembrolizumab in resectable stage III–IV melanomas

Presented By

Dr Sapna Patel, MD Anderson Cancer Center, TX, USA

Survival-benefit of neoadjuvant T-VEC maintained over 5 years of follow-up

Presented By

Prof. Reinhard Dummer, University of Zürich, Switzerland

Baseline ctDNA predicts survival in resected stage III–IV melanoma

Presented By

Prof. Georgina Long, University of Sydney, Australia

Genitourinary Cancer – Prostate Cancer

Overall survival benefit of abiraterone in mHSPC is maintained for 7 years

Presented By

Prof. Gerhardt Attard, UCL Cancer Institute London, UK

Limited benefit of adding long-term ADT to post-operative radiotherapy in prostate cancer

Presented By

Prof. Chris Parker, The Royal Marsden Hospital, UK

Intensified ADT benefits biochemical progression-free survival in biochemically relapsed prostate cancer

Presented By

Dr Rahul Aggarwal, University of California San Francisco, CA, USA

Genitourinary Cancer – Non-Prostate Cancer

Adjuvant nivolumab plus ipilimumab does not improve survival in patients with localised RCC at high risk of relapse after nephrectomy

Presented By

Prof. Robert Motzer, Memorial Sloan Kettering Cancer Center, NY, USA

Triple therapy improves progression-free survival in patients with advanced RCC versus dual therapy

Presented By

Prof Toni Choueiri, Dana-Farber Cancer Institute, MA, USA

Adjuvant atezolizumab does not improve outcomes for patients with RCC and increased risk of recurrence

Presented By

Dr Axel Bex, The Royal Free London NHS Foundation Trust, UK

Gynaecological cancers

OS benefit for advanced ovarian cancer patients treated with maintenance olaparib

Presented By

Prof. Isabelle Ray-Coquard, Centre Léon Bérard, France

Maintenance tegafur-uracil does not improve survival in locally advanced cervical cancer

Presented By

Prof. Keiichi Fujiwara, Saitama Medical University, Japan

Head and Neck Cancer

Adding first-line pembrolizumab to CRT in locally advanced HNSCC does not significantly prolong survival or event-free survival

Presented By

Prof. Jean-Pascal Machiels, Cliniques Universitaires Saint-Luc, Belgium

5-FU-free chemotherapy combination as an alternative for first-line treatment of recurrent or metastatic HNSCC

Presented By

Dr Marcin Dzienis, Gold Coast University Hospital, Australia

Epstein Barr virus-specific autologous cytotoxic T lymphocytes do not improve survival in nasopharyngeal carcinoma

Presented By

Dr Han Chong Toh, National Cancer Centre, Singapore

Table of Contents

Featured articles

Colorectal Cancer

Upper Gastrointestinal Cancer

Breast Cancer

Lung Cancer

Melanoma

Genitourinary Cancer – Prostate Cancer

Genitourinary Cancer – Non-Prostate Cancer

Gynaecological cancers

Head and Neck Cancer